The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for stakeholders considering the pharmaceutical sector. While its early success and creation of billions in earnings , the exclusivity lapse has opened the way for competing medications, significantly eroding profit potential . This change raises doubts about